Helpline Tollfree +1.800.650.8239 info@clearsynth.com

OUR QUALITY: ISO 9001:2015 | ISO 14001:2015 | OHSAS 18001:2007 | ISO Guide 34:2009 | ISO/IEC 17025:2005

We speak your language 

6-Fluoro Moxifloxacin

Impurities
CAT No.
:
CS-O-03571

CAS No.

:

268545-13-7

Molecular Weight

:

401.43

Molecular Formula

:

C21H24FN3O4

Purity

:

>98%

HS Code:

:

29049090

 


Useful information

"Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(\u2212) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a \"respiratory quinolone.\"

A United States patent application was submitted on 30 June 1989, for Avelox (moxifloxacin hydrochloride). In 1999 Avelox was approved by the U.S. Food and Drug Administration (FDA) for use in the United States.

In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis. Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. In the US, the marketing approval does not contain these restrictions, though the label contains prominent warnings against skin reactions.

Avelox (moxifloxacin) was launched in the United States in 1999 and is marketed in more than 80 countries worldwide. In the United States, Avelox is marketed by Bayer's partner Merck.

In 2011, the FDA added two box warnings for this drug in reference to spontaneous tendon ruptures and the fact that moxifloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and life-threatening breathing problems.",""



Product Application Notes

Impurity in commercial preparation of Moxifloxacin.



Synonyms

1cclopropyl-8-fluoro-6-methoxy-1,4-dihydro-7-[(4aS ,7aS )-ctahydro-6H -pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolincarboxylc cid.



References

The American Society of Health-System Pharmacists. Retrieved 3 April 2011;European Medicines Agency (24 July 2008)



MSDS



Have any questions ?

We normally respond within 8 hours.

Subject :

  Stock Status

  Bulk Pricing

  Custom QTY Quote

  Request MSDS

  Request COA

  Other






Page info:

This page contains information about 6-Fluoro Moxifloxacin Cas # 268545-13-7 and its Impurities.

6-Fluoro Moxifloxacin 6-Fluoro Moxifloxacin Worldwide Suppliers of 6-Fluoro Moxifloxacin Impurities Clearsynth 268545-13-7

Product rating: 9 6-Fluoro Moxifloxacin based on 20 ratings

  1. Impurities

  2. 6-Fluoro Moxifloxacin



Keywords

Keywords: Impurities 1cclopropyl-8-fluoro-6-methoxy-1,4-dihydro-7-[(4aS ,7aS )-ctahydro-6H -pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolincarboxylc cid. CS-O-03571 6-Fluoro Moxifloxacin Moxifloxacin 268545-13-7 401.43 C21H24FN3O4
Internal standard, Internal standard Moxifloxacin, HPLC-MS method validation, HPLC-MS method validation Moxifloxacin, LC-MS-MS method validation, LC-MS-MS method validation Moxifloxacin, Deuterated internal standard, Deuterated internal standard Moxifloxacin, Deuterated Moxifloxacin, Deuterium labeled Moxifloxacin, Quantitative bioanalytical methods, Quantitative bioanalytical methods Moxifloxacin, Blood samples Moxifloxacin, Blood concentrations, Heavy drugs, Analysis, Analysis Moxifloxacin, Clinical diagnostic, Clinical diagnostic Moxifloxacin, Dosing Moxifloxacin, Analytical method development, Internal standard method.



Related result for '6-Fluoro Moxifloxacin'

- Moxifloxacin : API Standards

- Moxifloxacin : Stable Isotopes

- Moxifloxacin : Metabolites

- Moxifloxacin : Impurities

- Moxifloxacin : Glucuronides

- Moxifloxacin : Intermediates



QUICK ENQUIRY

Specific product requirements



Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form :(






NORTH AMERICAN SALES AND R&D CENTRE

CLEARSYNTH CANADA INC.
2395 Speakman Drive,
Lab: 1001, Mississauga, ON,
Canada L5K 1B3
T : +1-289-729-0060

ASIA R&D CENTRE

CLEARSYNTH RESEARCH CENTRE
Plot No. 177, IDA, Mallapur,
Hyderabad- 500076,
Telangana, India.
T : +91-40-27155481

ASIA OFFICE

CLEARSYNTH LABS LTD
17, Lotus Business Park,
Andheri (W), Mumbai - 400053
India
T : +91-22-45045945